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1. Abbreviations 
AP-1 activator protein 1 
BMCP basophil and mast cell progenitor 
BMMC bone marrow-derived mast cell  
CIA collagen-induced arthritis  
cIAP cellular inhibitor of apoptosis protein 
CPA3 carboxypeptidase A3  
CTMC connective tissue mast cell  
DC dendritic cell  
DTA diphtheria toxin A 
DTR diphtheria toxin receptor  
DUB deubiquitinating enzyme 
E1  ubiquitin-activating enzyme   
E2  ubiquitin-conjugating enzyme   
E3  ubiquitin ligase  
EAE experimental autoimmune encephalomyelitis  
FcεRI high affinity IgE receptor 
GWAS genome wide association study  
HECT homologous to E6-associated protein carboxyl terminus  
Ig  immunoglobulin   
IKK  IκB kinase   
IL  interleukin   
IL-1R IL-1 receptor 
IL-33R IL-33 receptor  
IRF interferon regulated factor  
ITAM  immunoreceptor tyrosine-based activation motif 
ITIM immunoreceptor tyrosine-based inhibitory motif  
IκB  inhibitor of NF-κB   
LPS  lipopolysaccharide   
LUBAC  linear ubiquitin chain assembly complex   
MAP  mitogen-activated protein   
MMC  mucosal mast cell  
mMCP  murine mast cell protease  
MS  multiple sclerosis   
MyD88  myeloid differentiation primary response gene 88   
NF-κB nuclear factor-κB   
NFAT   nuclear factor of activated T cells   
NIK  NF-κB-inducing kinase   
OTU  ovarian tumor   
PKC  protein kinase C   
PLC  phospholipase C   
RBR  RING-in-between-RING   
RING  really interesting new gene   
Abbreviations  
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SCF  stem cell factor   
SLE  systemic lupus erythematosus   
SNARE  soluble N-ethylmaleimide-sensitive factor attachment protein receptor   
SNP  single nucleotide polymorphism   
TAD  transcription activation domain   
Th2  T helper type 2   
TIR  Toll/IL-1 receptor   
TLR  Toll-like receptor   
TNF  tumor necrosis factor 
TNFAIP  TNF α-induced protein  
TNFR  TNF receptor   
TRAF  TNFR-associated factor   
UBAN ubiquitin binding in ABIN and NEMO 
W  white spotting   
ZnF zinc finger   
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3. Summary  
The immune system defends its host against various pathogens, including viruses, 
bacteria, fungi and parasites. In addition, it plays important roles in the protection 
against and avoidance of noxious substances. Although appropriate immune 
responses are essential for host fitness, exaggerated or misdirected reactions 
against self- or seemingly harmless non-self antigens (allergens) can have 
detrimental outcomes, as seen in inflammatory, autoimmune and allergic diseases. 
The latter are often characterized by the production of allergen-specific IgE 
immunoglobulins. Mast cells are well known key players in IgE-dependent 
anaphylactic responses. In addition, they have also been implicated in playing a 
pathological role in various inflammatory and autoimmune diseases. However, this 
notion is controversial as it is primarily based on studies in mice that lack mast cells 
due to mutations in the receptor tyrosine kinase c-Kit.  
To dissect the contribution of mast cells to allergic, inflammatory and 
autoimmune diseases, I established the first gain-of-function mouse model for 
hyperactive mast cells by specifically ablating the ubiquitin-editing enzyme A20. This 
caused enhanced NF-κB activation downstream of TLRs, the IL-33R and the 
IgE:FcεRI module and thereby selectively enhanced pro-inflammatory mast cell 
reactions without affecting their degranulation. As a result A20-deficient mast cells 
exacerbated allergic lung and skin inflammation, and collagen-induced arthritis. In 
contrast, IgE-dependent immediate anaphylaxis reactions and experimental 
autoimmune encephalomyelitis were unaffected. These results demonstrate for the 
first time the consequences of enhanced inflammatory mast cell responses and 
provide evidence that mast cells can contribute to disease pathology (Publication I). 
In addition, I evaluated the biochemical consequences of A20 loss in B cells, which 
resulted in prolonged NF-κB activation leading to their pronounced hyperactivation 
(Publication II). Furthermore, I characterized a novel mouse strain expressing a 
tamoxifen-inducible version of the Cre recombinase under control of the endogenous 
c-Kit locus. This allowed specific and efficient inducible gene targeting in mast cells 
and enabled the study of mast cell differentiation and maintenance (Publication III). 
In summary, these novel mouse models yielded important insights into mast 
cell biology and allowed a dissection of the pathological contribution of mast cells to 
inflammatory diseases. 
Introduction 
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4. Introduction 
 Mast Cell Biology 4.1.
4.1.1. Mast Cell Development 
 
More than 130 years ago Paul Ehrlich described mast cells in connective tissues 
based on the histological staining patterns of basic aniline dyes. Due to their 
characteristic morphology with numerous cytosolic granules (Figure 1) he named 
them mast cells, assuming that their granules reflect the tissue’s nutritional or 
fattening state (in German “Mast”) (Vyas and 
Krishnaswamy, 2006).  
The developmental origin of mast cells 
remained unclear for a long time. It was initially 
believed that they arise from fibroblasts until bone 
marrow transplantation experiments hinted at 
their hematopoietic origin (Kitamura et al., 1978; 
1977). It is now well established that mast cells 
are indeed innate immune cells and hence as all 
other cells of the immune system are derived 
from hematopoietic stem cells (Figure 2) (Arinobu 
et al., 2005; Chen et al., 2005; Franco et al., 
2010; Qi et al., 2013). The exact developmental route of mast cells and their 
relationship to basophils still remains controversial. On the one hand, it was 
proposed that they share a common progenitor with neutrophils and macrophages 
(Suda et al., 1983) or with basophiles in the bone marrow or spleen (Arinobu et al., 
2005; Qi et al., 2013). On the other hand, a mast cell-committed progenitor with a 
closer developmental relationship to the megakaryocyte/erythrocyte lineage has also 
been discussed (Chen et al., 2005; Franco et al., 2010). 
Mast cells, unlike granulocytes and monocytes, do not complete their 
maturation in the bone marrow and do not circulate in the blood in a mature form 
(Gurish and Austen, 2012). This implies that their lineage-committed precursors 
migrate to peripheral tissues, where they undergo final differentiation under the 
 
Figure 1. Mast cell ultrastructure. 
Transmission electron micrograph of 
a mouse peritoneal mast cell. Scale 
bar: 2 μm. Taken from Taketomi et 
al. (2013). 
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influence of tissue-specific growth factors and proliferate locally (Figure 2) (Tsai et al., 
1991). Interestingly, these mast cell precursors peak in number in fetal blood at day 
15 of gestation, seed the fetal skin and mature locally (Hayashi et al., 1985; 
Rodewald et al., 1996). In the adult, their precursors are rarely detectable in blood, 
whereas mature mast cells can be found in essentially all tissues exposed to the 
environment, including the skin, the serosal cavities (e.g., the pleural and peritoneal 
cavities), and the respiratory and gastrointestinal tracts (Gurish and Austen, 2012). In 
these tissues mast cells are located in close proximity to blood vessels, nerves, 
smooth muscle cells, glands and hair follicles (Abraham and St John, 2010). 
 
4.1.2. Mast Cell Subsets and their Homeostasis 
 
In peripheral tissues mast cells are not a homogenous population, rather they exhibit 
a considerable degree of heterogeneity. In rodents, two major subsets of mast cells 
have been described, based on differences in their development, localization, 
granular content and pharmacologically induced degranulation (Kitamura, 1989). 
Connective tissue mast cells (CTMCs) constitutively reside in the dermis of the skin, 
the serosal cavities, and the submucosa of the gastrointestinal tract (Gurish and 
Austen, 2012). In contrast, mucosal mast cells (MMCs) are induced during certain 
allergic reactions or intestinal worm infections and reside intraepithelially in the gut or 
 
 
Figure 2. Mast cell development and subsets. Hematopoietic stem cells (HSC) give rise to 
immature blood-circulating mast cell progenitors (MCP) that enter peripheral tissues and 
differentiate locally. While mucosal mast cells are induced in the gut or respiratory mucosa upon 
allergic reactions and parasite infections, connective tissue mast cells are constitutively present in 
the submucosa. Modified from Galli et al. (2008). 
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respiratory mucosa (Figure 2) (Lantz et al., 1998; Xing et al., 2011). In their granules, 
mast cells store a large array of highly potent compounds including vasoactive 
amines, such as histamine and serotonin, proteoglycans and neutral proteases. 
While CTMCs express the proteoglycan heparin, the granules of MMCs mainly 
contain chondroitin sulfate (Gurish and Austen, 2012; Kitamura, 1989). Besides 
proteoglycans the main protein content of mast cell granules are neutral proteases 
that can be categorized into three classes, namely the metalloproteinase 
carboxypeptidase A3 (CPA3) and the murine serine mast cell proteases (mMCP), 
which have chymotryptic (chymases) or tryptic (tryptases) activities (Gurish and 
Austen, 2012). Murine CTMCs express CPA3, the chymases mMCP-4 and mMCP-5, 
and the tryptase mMCP-6 (Xing et al., 2011). In contrast, helminth-induced MMCs in 
the intestine express only the chymases mMCP-1 and mMCP-2 (Friend et al., 1996). 
Mast cells in the trachea and proximal airways provoked by allergic reactions express 
a broad range of proteases, which indicates a considerable degree of phenotypic 
plasticity (Xing et al., 2011). Hence, the protease phenotype of mast cells seems to 
be also regulated by the local environment and cytokine milieu. 
The in vivo development and/or homeostasis of both CTMCs and MMCs 
strongly depends on signals from the receptor tyrosine kinase c-Kit, which is encoded 
by the white spotting (W) locus (Rodewald and Feyerabend, 2012). In the 
hematopoietic system c-Kit is mainly expressed by progenitors in the bone marrow 
(Rodewald and Feyerabend, 2012). Its expression declines in most cell types during 
differentiation but remains prominent through all stages of mast cell development 
(Arinobu et al., 2005; Rodewald et al., 1996). Hence, various compound hypomorphic 
c-Kit mutations result in profound CTMC and MMC deficiency (Grimbaldeston et al., 
2005; Kitamura et al., 1978). In addition, mast cells are also absent in mice with 
mutations in the steel locus that encodes for the c-Kit ligand stem cell factor (SCF) 
(Kitamura and Go, 1979). While c-Kit transmitted signals are essential for in vivo 
development, interleukin-3 (IL-3) is sufficient for the differentiation of bone marrow-
derived mast cells (BMMCs) in vitro (Gurish and Austen, 2012). However, IL-3 is 
dispensable for mast cell development in vivo under steady-state conditions, but 
drives mastocytosis upon infection with intestinal nematodes (Lantz et al., 1998). In 
addition, IL-4, IL-9, IL-10, IL-33, lipid mediators and immunoglobulin (Ig)E might 
further support the maturation and enhance the survival of mast cells in peripheral 
tissues (Gurish and Austen, 2012; Kashiwakura et al., 2011; Taketomi et al., 2013). 
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4.1.3. Mast Cell Activation and Signaling Pathways 
 
Mast cells prominently express the high affinity IgE receptor (FcεRI) allowing them to 
capture circulating IgE. While priming with IgE per se has been shown to enhance 
mast cell survival, maturation, cytokine release and FcεRI expression (Kashiwakura 
et al., 2011), crosslinking of the IgE-bound FcεRI causes very prominent mast cell 
activation. The FcεRI is a heterotetrameric complex consisting of one α chain that 
binds IgE, one β chain and two γ chains that both possess signal transduction 
function through immunoreceptor tyrosine-based activation motifs (ITAMs) in their 
cytoplasmic tails (Figure 3) (Gilfillan and Tkaczyk, 2006; Kraft and Kinet, 2007). 
Crosslinking of the IgE-bound FcεRI leads to ITAM phosphorylation by receptor-
associated Src tyrosine kinase family members (Gilfillan and Tkaczyk, 2006; Kraft 
and Kinet, 2007). The subsequent recruitment and activation of the kinase Syk 
induces various signal transduction pathways via the phosphorylation of multiple 
adaptor and scaffolding proteins (Gilfillan and Tkaczyk, 2006; Kraft and Kinet, 2007). 
These proximal signaling events lead to the activation of phosphatidylinositol 3-
kinase, mitogen-activated protein (MAP) kinases (ERK, JNK, p38) and 
phospholipase C (PLC), which in turn control the activation of protein kinase C (PKC) 
isoforms through the generation of secondary messengers (1,2-diacylglycerol, 
inositol-1,4,5-triphosphate, and free cytosolic Ca2+) (Gilfillan and Tkaczyk, 2006; 
Klemm et al., 2006; Kraft and Kinet, 2007). The transient increase in cytosolic Ca2+ 
from intracellular endoplasmic reticulum stores is prolonged and potentiated through 
store-operated calcium channels in the plasma membrane and the entry of 
extracellular Ca2+ (Vig et al., 2008). These initial events cause three major 
downstream effector responses in mast cells (Figure 3) (Klemm et al., 2006): (1) 
Active PKC and free cytosolic Ca2+ synergistically induce the fusion of granules with 
the plasma membrane and the release of granular content, a process termed 
compound exocytosis or degranulation (Lorentz et al., 2012); (2) Free cytosolic Ca2+ 
and phosphorylation by MAP kinases activate cytosolic phospholipase A2 which 
initiate the biosynthesis of pro-inflammatory lipid mediators (including PGD2, PGE2, 
LTB4 and LTC4) by the release of arachidonic acid from phospholipids (Gilfillan and 
Tkaczyk, 2006); and (3) FcεRI crosslinking leads to the activation of various 
transcription factors, including activator protein 1 (AP-1), nuclear factor of activated T 
cells (NFAT) and nuclear factor (NF)-κB, thereby controlling late phase responses 
through the induction of gene expression. This results in the production of pro-
Introduction 
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inflammatory cytokines and chemokines (Gilfillan and Tkaczyk, 2006). To modulate 
FcεRI-induced signal transduction, mast cells express several inhibitory receptors 
such as FcγRIIB, SIRPα and Allergin-1 (Hitomi et al., 2010; Kraft and Kinet, 2007). 
These share a common cytoplasmic immunoreceptor tyrosine-based inhibitory motif 
(ITIM) that can recruit various phosphatases and suppress activating signaling 
pathways (Kraft and Kinet, 2007). 
Although FcεRI crosslinking causes arguably most prominent mast cell 
activation, other activating stimuli also shape mast cell effector responses. In 
agreement, FcεRI expression happens late during murine mast cell development 
when cells are already lineage committed (Arinobu et al., 2005; Rodewald et al., 
1996) and the acquisition of FcεRI was a relatively late event in evolution that 
coincided with the appearance of IgE immunoglobulins in mammals (Crivellato and 
Ribatti, 2010). Phylogenetic studies identified potential mast cell precursors, which 
release histamine, heparin and tryptase upon activation indicating that they might 
fight microbial infections (Crivellato and Ribatti, 2010). Indeed, murine mast cells also 
express molecules of such ancient immune defense systems, in particular pattern 
recognition receptors of the Toll-like receptor (TLR) family (Matsushima et al., 2004). 
TLRs serve as sensors that recognize invariant pathogen-associated molecular 
patterns and are hence essential to combat infections (Kawai and Akira, 2010). For 
example TLR3, TLR4 and TLR9 recognize viral double-stranded RNA, the bacterial 
cell wall component lipopolysaccharide (LPS), and unmethylated viral or bacterial 
 
 
Figure 3: Model of FcεRI 
signaling. FcεRI 
aggregation triggers 
proximal phosphorylation 
events leading to the 
generation of various 
secondary messengers. 
These in turn activate PKC 
isoforms and cause three 
main mast cell effector 
responses: Biosynthesis of 
lipid mediators, induction of 
gene transcription (NF-κB 
activation) and 
degranulation. Modified 
from Klemm and Ruland 
(2006). 
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CpG DNA, respectively (Kawai and Akira, 2010). In addition, mast cells can sense 
inflammation and tissue damage by expressing receptors recognizing IL-1 (IL-1R) 
and IL-33 (IL-33R), respectively (Schmitz et al., 2005). IL-33 is a recently identified 
member of the IL-1 family that is released upon tissue damage such as necrosis and 
hence seems to function as an alarmin (Moussion et al., 2008). Since mast cells 
express high levels of the IL-33Rα chain (ST2), they can rapidly respond to cell injury 
and recruit other immune cells to sustain inflammation or initiate tissue repair 
processes (Enoksson et al., 2011; Moritz et al., 1998). Engagement of TLRs, the IL-
1R and the IL-33R triggers a signaling cascade via the recruitment of various adaptor 
proteins including myeloid differentiation primary response gene 88 (MyD88). This 
leads to the activation of MAP kinases and NF-κB, resulting in pro-inflammatory gene 
expression (Matsushima et al., 2004; Schmitz et al., 2005; Vallabhapurapu and 
Karin, 2009). Certain TLR ligands and IL-33 have also been implicated in triggering 
mast cell degranulation (Komai-Koma et al., 2012; Supajatura et al., 2002). 
Additionally, mast cells can be activated by complement components, adenosine, 
cytokines and chemokines (Gilfillan and Tkaczyk, 2006). 
 
4.1.4. Genetic Mouse Models to Study Mast Cell in Vivo Functions  
 
Mast cells can be studied in vivo by perturbing their functions using pharmacological 
approaches. Although this is of clinical interest and has some advantages with 
respect to reversibility and temporal control, systemically or locally administered 
agents might cause unwanted side effects that have to be taken into account when 
interpreting data from such studies. As an example, small molecules that inhibit the 
tyrosine kinases c-Kit or Syk lack mast cell specificity (Juurikivi et al., 2005; 
Matsubara et al., 2006) and the efficiency of the ‘mast cell stabilizer’ cromolyn in 
preventing degranulation (Orr and Cox, 1969) has recently been questioned (Oka et 
al., 2012). Genetic approaches therefore represent the method of choice to study and 
characterize mast cell functions in vivo. To date, two Kit mutant mast cell-deficient 
mouse strains, KitW/Wv and KitW-sh/W-sh, are most widely used (Kawakami, 2009). The 
W mutation results in a truncated c-Kit protein lacking the transmembrane domain, 
which is not expressed on the cell surface and has the characteristics of a null allele 
(Nocka et al., 1990); the Wv mutation encodes for dominant loss-of-function point 
Introduction 
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mutation in the c-Kit kinase domain (Nocka et al., 1990); and the W-sh mutation is an 
inversion within the 5’ regulatory region of the c-Kit gene locus (Nigrovic et al., 2008).  
Besides mast cells, c-Kit is expressed by numerous other cells of 
hematopoietic and non-hematopoietic origin (Rodewald and Feyerabend, 2012). 
Hence, KitW/Wv and KitW-sh/W-sh mice have several abnormalities in and outside of the 
hematopoietic system that are not related to mast cell deficiency. Both mouse strains 
lack intestinal cells of Cajal and skin melanocytes, resulting in non-pigmented white 
fur. Moreover, KitW/Wv mice are sterile, anemic, have reduced numbers of neutrophils, 
basophils, megakaryocytes and intraepithelial γδ T cells, and suffer from dermatitis, 
gastric ulcers and dilatation of the duodenum (Grimbaldeston et al., 2005; Mancardi 
et al., 2011; Nigrovic et al., 2008 and references within). In contrast, KitW-sh/W-sh mice 
are fertile, not anemic and do not suffer from spontaneous pathologies affecting the 
skin, stomach or duodenum. However, KitW-sh/W-sh mice have histologically abnormal 
and enlarged spleens with neutrophilia, basophilia, megakaryocytosis and 
thrombocytosis (Grimbaldeston et al., 2005; Mancardi et al., 2011; Nigrovic et al., 
2008). Due to a disruption in the Corin coding region KitW-sh/W-sh mice additionally 
develop mild cardiomegaly (Nigrovic et al., 2008). These multiple physiological 
defects that are not directly related to the lack of mast cells limit the interpretation of 
experimental results derived from these in vivo models. Yet, the mast cell deficiency 
of KitW/Wv and KitW-sh/W-sh mice can be selectively repaired by the adoptive transfer of 
in vitro generated mast cells (Grimbaldeston et al., 2005; Nakano et al., 1985). These 
mast cell reconstituted mice, also termed ‘mast cell knock-in mice’, have been used 
for separating general Kit-dependent but mast cell-independent abnormalities from 
bona fide mast cell functions. Despite all these limitations, most of our knowledge on 
mast cell in vivo function has been gathered over the last decades from mast cell-
deficient and mast cell-reconstituted KitW/Wv or KitW-sh/W-sh mice (Kawakami, 2009).  
Recent advances in gene targeting approaches led to the development of 
novel tools to manipulate the genome of mast cells using the Cre/loxP technology. 
Several groups utilized the regulatory elements of mast cell protease genes 
(Feyerabend et al., 2011; Lilla et al., 2011; Müsch et al., 2008; Scholten et al., 2008) 
or the FcεRIβ chain (Furumoto et al., 2011) to drive constitutive expression of the 
Cre recombinase. With these mice mast cell-specific conditional gene manipulation 
has been accomplished to various degrees of efficiency and specificity. In addition, 
these mice were used to generate novel Kit-independent models of mast cell 
deficiency. Scholten et al. generated bacterial artificial chromosome transgenic mice 
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with Cre under the control of the Mcpt5 gene locus (Mcpt5Cre) and hence expression 
is limited to mast cells expressing the chymase mMCP-5 (Scholten et al., 2008). This 
allowed mast cell-specific expression of the diphtheria toxin A (DTA) subunit resulting 
in constitutive CTMC ablation. In addition, Cre-mediated expression of the human 
diphtheria toxin receptor (DTR) permitted inducible selective depletion of CTMCs 
upon diphtheria toxin injections (Dudeck et al., 2011). Müsch et al. generated a 
transgenic mouse line with Cre under the control of a 600 bp baboon α-chymase 
promoter fragment (Chm:Cre). A LacZ reporter strain indicated that recombination 
was limited to MMCs (Müsch et al., 2008). Lilla et al. generated mice harboring a 
transgene with Cre under the control of a 780 bp Cpa3 promoter fragment (Cpa3-
Cre). A florescent reporter strain revealed Cre-mediated recombination in various 
leucocytes in addition to mast cells (Lilla et al., 2011). To ablate mast cells, Cpa3-Cre 
mice were crossed to a conditional Mcl-1 allele encoding for a potent pro-survival 
member of the Bcl-2 family. This caused mast cell deficiency in Cpa3-Cre Mcl-1F/F 
mice but also basopenia, neutrophilia and macrocytic anemia (Lilla et al., 2011). 
Feyerabend et al. inserted Cre into the Cpa3 locus by homologous recombination 
(Cpa3Cre/+). Surprisingly, these mice did not allow mast cell-specific gene targeting 
but lacked all mast cell subsets in addition to a reduction in the number of basophils 
presumably due to Cre-mediated toxicity (Feyerabend et al., 2011). Similarly, 
Furumoto et al. used homologous recombination into the FcεRIβ chain locus to drive 
Cre expression in mast cells and basophiles with only limited efficiency (FcεRIβCre/+) 
(Furumoto et al., 2011). Finally, Otsuka et al. generated transgenic mice, in which 
DTR expression is driven by IL-4 promoter and enhancer fragments allowing the 
inducible ablation of all mast cell subsets in addition to basophils upon diphtheria 
toxin injections (Mas-TRECK) (Otsuka et al., 2011). These novel Kit-independent 
mast cell deficient mice will allow to reassess in vivo mast cell functions and will 
permit to dissect the role of specific genes using the Cre/loxP technology. 
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4.1.5. Mast Cells in Pathologies 
 
Based on correlative studies in human patients and genetic mouse models such as 
KitW/Wv and KitW-sh/W-sh mice, mast cells have been implicated in various pathologies 
including allergic, inflammatory and autoimmune diseases (Brown and Hatfield, 2012; 
Galli and Tsai, 2012). 
 
4.1.5.1. Mast Cells in Allergic Responses 
 
Allergic diseases, including atopic dermatitis, food allergies, allergic rhinitis and 
allergic asthma, are considered to be abnormal or misdirected immune responses 
against seemingly harmless non-self antigens (allergens) (Galli and Tsai, 2012). 
These reactions closely resemble type 2 immune responses, which are generated 
upon intestinal helminth infection, and are characterized by activation of epithelial 
barriers, goblet hyperplasia and mucus production, polarization of T helper type 2 
(Th2) cells and increased serum levels of IgG1 and IgE, accompanied by the 
activation of basophils, eosinophils and mast cells (Galli and Tsai, 2012). Mast cells 
are well known effector cells in IgE-associated reactions. Through crosslinking of the 
IgE-bound FcεRI by multivalent allergens, mast cells contribute to early-phase 
allergic reactions (type I immediate hypersensitivity reactions) by the rapid release of 
preformed mediators such as vasoactive amines and the production of pro-
inflammatory lipid mediators (Feyerabend et al., 2011; Klemm et al., 2006). In severe 
cases, exaggerated immediate allergic hypersensitivity reactions can cause life-
threatening anaphylaxis in susceptible hosts (Rodewald and Feyerabend, 2012). In 
addition, mast cells participate in late-phase allergic reactions by the production of 
pro-inflammatory lipid mediators and cytokines that orchestrate the recruitment of 
leucocytes to substantiate inflammation (Galli and Tsai, 2012; Klemm et al., 2006). 
During allergic asthma the host is repeatedly exposed to allergens causing early- and 
late-phase reactions that result in inflammation and airway remodeling (Galli and 
Tsai, 2012). Mast cell numbers increase during asthma (Brightling et al., 2002) and in 
rodent asthma models using KitW/Wv and KitW-sh/W-sh mice, mast cells were shown to 
be essential for disease induction when sensitization to model allergens occurred 
under mild conditions (Nakae et al., 2007; Williams and Galli, 2000). In this context 
mast cells might be stimulated by IgE-dependent and -independent pathways (Galli 
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and Tsai, 2012; Mayr et al., 2002). In the latter scenario, they might be activated by 
TLR ligands or IL-33 to exacerbate disease pathology (Galli and Tsai, 2012). 
However, in addition to playing a pathological role, several reports also implicated 
mast cells in dampening allergic inflammation by protease-mediated cleavage of IgE, 
IL-13 or IL-33, making their exact function a matter of debate (Rauter et al., 2008; 
Waern et al., 2013; 2012). 
Allergic reactions are generally considered to be detrimental misdirected type 
2 immune responses originally designed to protect the host from macroparasites 
However, they could also be part of a more general defense mechanism against 
noxious substances, xenobiotics and irritants (Palm et al., 2012). Indeed, mast cells 
have been shown to degrade bee, snake, gila monster and scorpion venoms through 
the secretion of granule-associated proteases (Akahoshi et al., 2011; Metz et al., 
2006). It remains to be determined if mast cells are directly activated by venoms 
(Metz et al., 2006) or if a protective IgE-dependent immune response is required and 
in this context mast cells are activated through the FcεRI (Marichal et al., 2013; Palm 
et al., 2013). In addition to the secretion of proteases mast cells rapidly release 
histamine upon activation. This causes vasodilatation through its effect on the 
endothelium, leads to bronchoconstriction and enhances peristaltic movement by 
acting on smooth muscle cells, and provokes itch by stimulating nerve endings 
(Thurmond et al., 2008). These effects could lead to the dilution of venoms, expulsion 
of noxious particles by sneezing, coughing, tearing, vomiting and diarrhea, and itch-
mediated mechanical removal of ectoparasites such as ticks (Palm et al., 2012). 
Therefore, mast cell-dependent allergic reactions might not only be detrimental but 
could also be beneficial for the host. Along the same line, allergic anaphylaxis 
reactions might be overshooting responses analogous to fatal septic shock and 
exaggerated inflammation upon bacterial infection. 
 
4.1.5.2. Mast Cells in Autoimmune Diseases 
 
In addition to allergic reactions mast cells have been implicated in playing a 
pathological role in various autoimmune diseases. When work on this thesis 
commenced, prominent roles for mast cells were suggested for multiple sclerosis 
(MS) and rheumatoid arthritis (Brown and Hatfield, 2012; Sayed et al., 2008). 
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MS, a chronic inflammatory disease of the central nervous system, is 
characterized by a breakdown of the blood-brain barrier, mononuclear and T cell 
infiltration, extensive demyelination and the formation of lesions consisting of fibrous 
plaques (Hauser and Oksenberg, 2006). This ultimately causes impairment in various 
sensory, motor and other neural functions (Hauser and Oksenberg, 2006). 
Accumulation of mast cells or mast cell-associated transcripts have been detected in 
these lesions (Sayed et al., 2008). In addition, mast cells seem to be activated, as 
suggested by high levels of tryptase and histamine in the cerebrospinal fluid of MS 
patients (Sayed et al., 2008). Degranulated mast cells were also detected in the 
central nervous system of animals suffering from experimental autoimmune 
encephalomyelitis (EAE), a rodent model for MS (Brenner et al., 1994). An essential 
contribution to this disease was proposed based on studies using pharmacological 
inhibition (Dimitriadou et al., 2000) or the analysis of mast cell-deficient KitW/Wv mice 
(Secor et al., 2000). These mice showed reduced disease incidence, delayed onset 
and milder symptoms in comparison to control animals, all of which could be restored 
upon intravenous mast cell reconstitution (Secor et al., 2000). Several mechanisms 
have been proposed for how mast cells influence the outcome of EAE. Mast cells are 
thought to degrade myelin through the release of proteases, influence permeability of 
the blood brain barrier by the secretion of histamine (Sayed et al., 2008) and 
enhance the recruitment of neutrophils and T cells through tumor necrosis factor 
(TNF) release (Sayed et al., 2010). However, as transferred mast cells did not 
repopulate the central nervous system, despite restoring susceptibility in KitW/Wv mice 
(Tanzola et al., 2003), it was proposed that they could also exert their function in the 
periphery by functioning as antigen presenting cells to generate an adaptive T cells 
response or influence the function of dendritic cells (DCs) (Sayed et al., 2008). 
During EAE, mast cells might become activated by scavenger receptor-mediated 
detection of myelin (Medic et al., 2008) or through activating Fc receptors and TLRs 
(Brown et al., 2002; Sayed et al., 2008). 
Rheumatoid arthritis is an autoimmune disease characterized by chronic joint 
inflammation, synovial hyperplasia and immune cell infiltrations leading to bone and 
cartilage destruction. In recent years, much progress has been made in identifying 
molecular players of the disease, but the exact etiology still remains incompletely 
understood (Eklund, 2007). Correlative studies in human patients identified mast cells 
at sites of cartilage erosion and their numbers correlate with disease severity 
(Eklund, 2007). Several rodent models are used to study arthritis pathology, including 
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serum transfer and active induction models (Lee et al., 2002; Pitman et al., 2011). 
Transfer of autoantibody-containing serum from K/BxN mice, which spontaneously 
develop arthritis, induces disease pathology in recipient mice in a manner that 
depends on the alternative complement pathway, Fc receptors, neutrophils and the 
pro-inflammatory cytokine IL-1 (Nigrovic and Lee, 2007). Using this model Lee and 
colleagues demonstrated that KitW/Wv mice were completely protected from arthritis 
induction and susceptibility could be selectively repaired upon mast cell reconstitution 
(Lee et al., 2002). In this context, mast cells have been proposed to aggravate 
disease pathology by leukocyte recruitment through the release of LTB4, TNF, IL-1 
and tryptase, promoting vascular permeability, generating local inflammation, or the 
destruction of synovium and bone (Brown and Hatfield, 2012; Eklund, 2007; Nigrovic 
and Lee, 2007; Xu et al., 2008). During disease, mast cells might be activated by Fc 
or complement receptors (Nigrovic and Lee, 2007). Moreover, the recently identified 
pro-inflammatory alarmin IL-33 might play an important role in the induction of 
arthritis (Palmer and Gabay, 2011) and it has been proposed that IL-33 fulfills its 
function at least in part by activating mast cells (Xu et al., 2008). Collectively, our 
current understanding of in vivo mast cell functions during autoimmune diseases are 
derived from correlative studies in human patients and mainly one experimental 
system, namely mast cell-deficient KitW/Wv mutant mice. However, the pathological 
contribution of mast cells to autoimmune diseases is not as well-defined as it might 
appear as several recent reports using different models of mast cell deficiency have 
challenged some of these initially proposed findings (Bennett et al., 2009; Li et al., 
2011; Piconese et al., 2011; Zhou et al., 2007). 
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 Regulation of NF-κB Activation by the Ubiquitin-4.2.
Editing Enzyme A20 
4.2.1. The Ubiquitin System 
 
Ubiquitination, the covalent attachment of ubiquitin, is a reversible and dynamic post-
translational modification involved in various cellular processes, including signal 
transduction, protein turnover, DNA repair, cell-cycle control, receptor endocytosis 
and vesicle trafficking (Dikic et al., 2009). Ubiquitination of substrate proteins is 
brought about by a three-step enzymatic cascade catalyzed by ubiquitin-activating 
enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s) 
(Figure 4) (Hershko and Ciechanover, 1998; Malynn and Ma, 2010). The E1s initiate 
this process in an ATP-dependent reaction leading to the formation of a thioester 
bond between the carboxy group of the C-terminal glycin residue and a cysteine in 
the E1’s active center. The activated ubiquitin is then transferred to an E2, which, in 
combination with an E3 ligase, attaches ubiquitin to a substrate protein by forming an 
isopeptide bond between the C-terminus of ubiquitin and, typically, an ε-amino group 
of an internal lysine residue (K) (Dikic et al., 2009; Hershko and Ciechanover, 1998; 
Malynn and Ma, 2010). In humans, there are two E1s, approximately 40 E2s and 
more than 600 E3s (Malynn and Ma, 2010). Substrate specificity is mediated by E3 
ligases which, based on function, can be generally subdivided into two groups. One 
is the family comprising the really interesting new gene (RING) and the structurally 
related U-box proteins, which do not form a covalent thioester bond with ubiquitin but 
rather bring the activated E2 into proximity with a substrate and hence function as 
matchmakers. The other group contains homologous to E6-associated protein 
carboxyl terminus (HECT) E3 ligases that, in contrast, accept the activated ubiquitin 
and form a covalent intermediate before transfer. Similarly, a distinct set of E3s that 
contain a RING-in-between-RING (RBR) domain might use a HECT-like mechanism 
for the transfer of ubiquitin (Komander and Rape, 2012).  
Substrate proteins can be modified with a single ubiquitin moiety 
(monoubiquitination), with multiple single ubiquitin moieties (multimonoubiquitination), 
or with polymeric chains (polyubiquitination) (Dikic et al., 2009; Komander and Rape, 
2012). The latter modification is generated through successive addition of ubiquitin to 
the N-terminal amino group (linear or M1-linked chains) or to one of the seven 
internal lysine residues (K6-, K11-, K27-, K29-, K33-, K48- or K63-linked chains) of 
Introduction 
 
22 
the previously attached ubiquitin (Dikic et al., 2009; Komander and Rape, 2012). 
These polyubiquitin chains adopt distinct conformations, which can be distinguished 
by linkage-specific ubiquitin-binding domains and hence fulfill different functions 
(Dikic et al., 2009; Komander and Rape, 2012). K11- and K48-linked chains both 
adopt a compact conformation and have been mainly studied in the context of 
targeting substrate proteins to the 26S proteasome for degradation (Figure 4) 
(Bremm et al., 2010; Eddins et al., 2007). In contrast, linear and K63-linked chains 
adopt an open topology with a high degree of conformational freedom and 
predominantly seem to fulfill non-proteolytic functions (Figure 4) (Komander et al., 
2009b). In addition to homotypic linkage types, heterotypic mixed and branched 
chains have been reported (Dikic et al., 2009). HECT domain-containing E3 ligases 
are thought to intrinsically dictate the linkage type, whereas, in case of RING or U-
box E3 ligases linkage specificity is determined by the E2 (Komander and Rape, 
2012). As an example, the E2 UBC13 together with the E2 variant UEV1a and the 
RING E3 ligase TNF receptor associated factor 6 (TRAF6) promotes the formation of 
K63-linked chains (Deng et al., 2000). In contrast, the E2 UBCH5 and the RING E3 
ligases cellular inhibitor of apoptosis protein 1/2 (cIAP1/2) can assemble chains with 
different topologies, such as K11-, K48- and K63-linked polyubiquitin chains (Dynek 
et al., 2010). The linkage type of linear polyubiquitin chains is thought to be 
intrinsically determined by the linear ubiquitin chain assembly complex (LUBAC), 
which consists of two RBR domain-containing proteins, HOIL-1 and HOIP, in addition 
to SHARPIN (Kirisako et al., 2006). 
 
 
Figure 4. The ubiquitin system. Ubiquitin is conjugated to substrate proteins in a manner 
dependent on the serial and coordinated action of three classes of enzymes (E1s, E2s and E3s). 
Attachment of monoubiquitin or of polyubiquitin chains, which adopt different topologies as a result 
of their linkage type, marks the modified protein for diverse biological consequences. As an 
example, K48- and K11-linked chains target proteins for proteasomal degradation, while linear and 
K63-linked chains promote the assembly of complexes. Deubiquitinating enzymes can remove 
conjugated ubiquitin moieties. Taken from Hymowitz and Wertz (2010). 
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Similar to phosphorylation, ubiquitination is a reversible protein modification 
(Figure 4). Ubiquitin moieties can be removed by deubiquitinating enzymes (DUBs). 
In humans, there are approximately 79 DUBs, which are either cysteine or 
metalloproteases (Komander et al., 2009a). DUBs fulfill several key functions in cells: 
they generate free ubiquitin from ubiquitin precursors; they recycle ubiquitin by 
removing chains from proteins that are substrates for degradation; and they can trim, 
edit and remove chains to regulate intracellular signaling events or rescue proteins 
from degradation (Komander et al., 2009a). 
 
4.2.2. The NF-κB Family of Transcription Factors 
 
The NF-κB family of transcription factors regulates innate and adaptive immunity as 
well as inflammatory reactions. It fulfills these pleiotropic functions through the 
transcriptional control of various genes that regulate proliferation, survival and 
inflammation (Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 2009; Wertz and 
Dixit, 2010). In mammals, the NF-κB family comprises five members: NF-κB1 (p50 
and its precursor p105), NF-κB2 (p52 and its precursor p100), RelA (p65), c-Rel and 
RelB. The family is characterized by an N-terminal Rel homology domain that allows 
homo- and heterodimer formation and is essential for binding to κB sites in promoters 
or enhancers of target genes. RelA and c-Rel largely heterodimerize with p50, 
whereas RelB binds p52 or its precursor p100. Only RelA, c-Rel and RelB 
additionally contain a C-terminal transcription activation domain (TAD) and can 
positively regulate transcription. As p50 and p52 lack this TAD, they might function as 
transcriptional repressors or activators depending on whether they bind to κB sites as 
homodimers or interact with TAD-containing NF-κB family members, respectively 
(Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 2009).  
NF-κB family members primarily interact with inhibitor of NF-κB (IκB) 
proteins, which consist of three groups: The classical IκB proteins, IκBα, IκBβ and 
IκBε, are characterized by the presence of multiple ankyrin repeats that mediate 
binding to NF-κB dimers and mask their nuclear localization sequence, hence 
sequestering them in the cytoplasm. Upon cellular activation the classical IκB 
proteins are rapidly degraded in a proteasome dependent fashion. This releases 
cytoplasmic NF-κB dimers that can now migrate into the nucleus and activate the 
transcription of various genes (Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 
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2009). The second group, the precursor NF-κB proteins p105 and p100 contain 
ankyrin repeats and thus can also function as inhibitors. In resting conditions the 
majority of p105 is constantly processed to generate the NF-κB family member p50, 
however, its full-length form p105 can retain NF-κB proteins such as RelA and c-Rel 
in the cytoplasm. These are liberated upon stimulation-induced phosphorylation of 
p105, leading to its complete proteasomal degradation. In contrast, p100 sequesters 
RelB in the cytoplasm. Activation-induced phosphorylation marks p100 for partial 
proteasome-mediated processing that results in the generation of the p52 fragment 
bound to RelB (Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 2009). The 
third group contains the atypical IκB proteins IκBNS, IκBζ and BCL-3, which are 
induced upon activation, primarily act in the nucleus and, depending on the context, 
might function as transcriptional repressors or activators (Ghosh and Hayden, 2008; 
Vallabhapurapu and Karin, 2009).  
 
4.2.3. Canonical and Alternative NF-κB Activation 
 
In general, two distinct signaling pathways mediate the activation of NF-κB 
transcription factors. The canonical pathway centers around the trimeric IκB kinase 
(IKK) complex that contains two catalytic subunits, IKK1 (also known as IKKα) and 
IKK2 (IKKβ), and the regulatory/scaffolding subunit NF-κB essential modulator 
(NEMO or IKKγ) (Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 2009; Wertz 
and Dixit, 2010). Various stimuli, such as microbial products, pro-inflammatory 
cytokines or signals from antigen receptors, activate the IKK complex (discussed 
below), which subsequently phosphorylates IκBα on specific serine residues, leading 
to its K48-linked polyubiquitination by the SCFβTrCP E3 ubiquitin ligase complex. 
Ubiquitinated IκBα is then degraded by the proteasome resulting in the liberation 
NF-κB heterodimers (Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 2009; 
Wertz and Dixit, 2010).  
The alternative or non-canonical NF-κB pathway is activated by a small 
subset of TNF family members and their receptors (TNFR), including the lymphotoxin 
β receptor, B cell-activating factor receptor and CD40. This pathway depends on the 
labile NF-κB-inducing kinase (NIK), which in non-stimulated cells is modified with a 
K48-linked polyubiquitin chain and is hence constantly degraded by the proteasome 
(Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 2009; Wertz and Dixit, 2010). 
However, upon receptor engagement, NIK is stabilized, accumulates and 
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phosphorylates IKK1. IKK1-mediated phosphorylation of p100 results in its 
processing to p52 and translocation of RelB:p52 heterodimers into the nucleus 
(Ghosh and Hayden, 2008; Vallabhapurapu and Karin, 2009; Wertz and Dixit, 2010).  
 
4.2.4. Activation of the IKK Complex Is Regulated by Ubiquitination  
 
Activation of the canonical NF-κB pathway is intimately regulated by ubiquitination 
(Skaug et al., 2009; Wertz and Dixit, 2010). Engagement of pattern-recognition, 
cytokine and antigen receptors leads to the assembly of polyubiquitin chains of 
various topologies including K63-linked and linear chains (Skaug et al., 2009; Wertz 
and Dixit, 2010). These receptor-proximal polyubiquitin chains are thought to function 
as molecular scaffolds and recruitment platforms for kinase complexes (Skaug et al., 
2009; Wertz and Dixit, 2010). In this context, the ubiquitin-binding motif of NEMO 
(ubiquitin binding in ABIN and NEMO, UBAN), which shows a preference for linear 
chains but can interact with K11-, K48- and K63-linked polyubiquitin chains, mediates 
recruitment of the IKK complex (Dynek et al., 2010). Similarly, the regulatory proteins 
TAB2/3 contain ubiquitin-binding domains, which interact with K63-linked 
polyubiquitinated substrates, and bring the associated kinase TAK1 into juxtaposition 
with the IKK complex (Kanayama et al., 2004). This induced proximity is thought to 
result in the phosphorylation and activation of IKK1/2 by TAK1. Alternatively, induced 
proximity of IKK1/2 per se could result in their phosphorylation in trans or 
conformational changes in NEMO upon ubiquitin binding might promote IKK1/2 
activation (Wertz and Dixit, 2010).  
Although canonical NF-κB activation universally depends on polyubiquitin 
chain assembly for proximal signal transduction, each receptor recruits a distinct set 
of adaptor proteins, kinases and E3 ligases. In the TNFR pathway, ligand-induced 
receptor trimerization leads to recruitment and polyubiquitination of the adaptor 
protein RIP1. In this context, TRAF2 and TRAF5 together with cIAP1/2 are thought to 
be the E3 ligases that mediate K63-polyubiquitination (Skaug et al., 2009; Wertz and 
Dixit, 2010). In addition, post TNFR engagement LUBAC modifies RIP1 and NEMO 
with linear polyubiquitin chains (Gerlach et al., 2011; Tokunaga et al., 2009). TLRs, 
the IL-1R and the IL-33R contain a common cytoplasmic motif, called the Toll/IL-1 
receptor (TIR) domain, and thus initiate NF-κB activation by related mechanisms. 
Engagement of these receptors results in the recruitment of the TIR domain-
containing protein MyD88, among other proximal adaptor proteins. This promotes the 
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activation of the E3 ligases TRAF6 and Pellino in a manner dependent on IRAK1/4 
and their subsequent K63-linked polyubiquitination (Skaug et al., 2009; Wertz and 
Dixit, 2010). Furthermore, canonical NF-κB activation initiated by IL-1 and certain 
TLRs depends on linear ubiquitination by LUBAC (Sasaki et al., 2013; Tokunaga et 
al., 2009). In case of ITAM-containing receptors such as antigen receptors expressed 
by B and T lymphocytes a proximal tyrosine phosphorylation cascade is initiated, 
resulting in the assembly of a complex containing CARMA1, Bcl-10 and MALT1. 
Recruitment and MALT1-induced oligomerization of TRAF6 has been proposed to 
regulate its E3 ligase activity, leading to the generation of K63-linked polyubiquitin 
chains (Skaug et al., 2009; Wertz and Dixit, 2010). Thus, a general scheme emerges 
whereby K63-linked polyubiquitin chains generated by receptor-specific E3 ligase 
complexes and linear chains assembled by LUBAC trigger activation of the IKK 
complex and canonical NF-κB signaling. 
 
4.2.5. Termination of NF-κB Responses  
 
Efficient and rapid NF-κB activation is essential for appropriate immune responses to 
combat infections. However, proper termination is needed to avoid uncontrolled, 
excessive or chronic inflammation as seen in septic shock or autoimmune diseases 
like rheumatoid arthritis (Ma and Malynn, 2012; Vereecke et al., 2009). Various 
regulatory mechanisms terminate NF-κB activation at all levels of signal transduction, 
from the modulation of receptor-proximal steps all the way to directly affecting the 
function of NF-κB in the nucleus (Renner and Schmitz, 2009). Classical IκB proteins 
such as IκBα are the main regulators of NF-κB activity and are themselves NF-κB 
target genes: they therefore function in a negative feedback loop (Vallabhapurapu 
and Karin, 2009). IκBα can interact with DNA-bound NF-κB dimers resulting in their 
inactivation and export from the nucleus (Vallabhapurapu and Karin, 2009). Other 
regulatory mechanism within the nucleus include degradation of RelA (Natoli and 
Chiocca, 2008) or binding of atypical IκB proteins such as IκBζ that modulate NF-κB 
transactivation (Vallabhapurapu and Karin, 2009). The regulation of more proximal 
events includes degradation of signaling components, generation of decoy receptors 
or dominant-negative signal transducers, and removal of activating post-translational 
modifications such as phosphorylation (Renner and Schmitz, 2009). Furthermore, 
NF-κB activation can be regulated at the level of ubiquitination. Clearly, ubiquitin-
Introduction 
 
27 
binding proteins such as ABINs, optineurin and A20 (discussed below) and DUBs 
such as CYLD, Cezanne, USP21, OTULIN and A20 (discussed below) play essential 
roles (Harhaj and Dixit, 2011; Keusekotten et al., 2013; Verstrepen et al., 2009). As 
an example, the tumor suppressor CYLD can cleave linear and K63-linked 
polyubiquitin chains and thereby is thought to target a large set of signaling 
components including TRAF2, TRAF6, NEMO and RIP1 to terminate NF-κB 
activation (Komander et al., 2009b; Harhaj and Dixit, 2011).  
 
4.2.6. A20 Is a Key Negative Regulator of Cellular Activation  
 
A20 was initially identified in endothelial cells as a gene that is rapidly and profoundly 
induced by TNF treatment (Dixit et al., 1990). Thus, A20 is also referred to as tumor 
necrosis factor α-induced protein (TNFAIP)3. Due to two κB sites in the A20 
promoter region (Krikos et al., 1992), A20 is additionally induced by other stimuli that 
activate NF-κB such as engagement of the IL-1R, CD40, TLRs, and B and T cell 
antigen receptors (Ma and Malynn, 2012; Vereecke et al., 2009). The important 
physiological functions of A20 were demonstrated by genetic disruption studies in 
mice. A20-deficient mice develop spontaneous severe multiorgan inflammation 
leading to perinatal lethality, which can be overcome by the elimination of MyD88-
dependent signals (Lee et al., 2000; Turer et al., 2008).  
A20 contains an N-terminal ovarian tumor (OTU) domain and seven C-
terminal zinc finger (ZnF) motifs, which are thought to harbor two opposed ubiquitin-
editing functions, namely DUB and E3 ligase activity (Wertz et al., 2004). It has been 
demonstrated that in the TNFR signaling pathway the OTU domain of A20 has DUB 
activity and removes K63-linked polyubiquitin chains from RIP1 (Figure 5) (Wertz et 
al., 2004). Similarly, A20 has been shown to remove K63-linked ubiquitin chains from 
TRAF6, RIP2 and MALT1 upon engagement of TLR4, the IL-17 receptor, NOD2 
receptors or the T cell receptor (Figure 5) (Boone et al., 2004; Duwel et al., 2009; 
Garg et al., 2013; Hitotsumatsu et al., 2008). Although A20 appears to be specific for 
K63-linked chains in a cellular context, in vitro it preferentially hydrolyses free K48-
linked polyubiquitin chains (Bosanac et al., 2010; Komander et al., 2009b; Lin et al., 
2008). This suggests that other proteins such as ABINs (Mauro et al., 2006) or 
TAX1BP1 (Shembade et al., 2007) might direct A20 to its targets or modulate its 
DUB activity in vivo. Alternatively, A20 might not show global DUB activity but rather 
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target specificity. Supporting this notion, A20 removes K63-linked chains from 
physiological substrates such as TRAF6. It does so by cleaving the TRAF6-ubiquitin 
isopeptide bond and hence seems to remove the K63-linked chain as a whole 
without disassembling it (Lin et al., 2008).  
In addition to using its DUB activity to remove K63-linked chains from RIP1 to 
terminate NF-κB activation upon TNFR engagement, A20 is also thought to 
assemble K48-linked chains on RIP1, thereby targeting it for proteasomal 
degradation (Figure 5) (Wertz et al., 2004) This E3 ligase activity was ascribed to 
ZnF4 (Wertz et al., 2004). It was therefore proposed that A20 functions in a 
sequential manner: A20 first removes activating K63-linked chains from RIP1 and 
then adds degradation-inducing K48-linked ubiquitin chains (Wertz et al., 2004). 
However, it is not clear whether ZnF4 possesses intrinsic E3 ligase activity, or if the 
A20 interacting E3 ligases Itch and RNF11 fulfill this function (Shembade et al., 2008; 
2009). To clarify the physiological contribution of A20’s dual enzymatic activities, 
knock-in mice were generated that express mutated A20 proteins (Lu et al., 2013). 
Both A20ZF4 (mutations within ZnF4) and A20OTU (mutation of the catalytic cysteine in 
the OTU domain to alanine) mice were outwardly normal, in contrast to A20-deficient 
 
 
Figure 5. A20 is a central negative regulator of NF-κB activation. Upon receptor engagement 
proximal signaling events and the generation of polyubiquitin chains with various topologies (K48, 
red; K63, blue; linear, green) lead to canonical NF-κB activation. A20 restricts multiple aspects of 
this signal transduction by the removal of activating K63-linked chains (from MALT1, RIP1, RIP2 and 
TRAF6), modification of proteins with degradation-inducing K48-linked chains (RIP1), disruption of 
E2:E3 ligase complexes (UBC13:TRAF6, UBCH5c:TRAF6 and UBC13:cIAP1) or competitive 
binding to K63-linked or linear chains. Modified from Catrysse et al. (2013). 
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mice that show chronic inflammation and perinatal lethality (Lee et al., 2000; Lu et al., 
2013). However, both A20ZF4 and A20OTU mice were hypersensitive to TNF injections, 
indicating that both domains contribute to some extent to A20’s ability to restrict 
inflammation (Lu et al., 2013).  
Since A20 mutants lacking the catalytic cysteine in the DUB domain can still 
inhibit NF-κB activation both in vitro and in vivo (Evans et al., 2004; Lu et al., 2013), 
additional non-catalytic mechanisms have been described. For example, A20 was 
shown to disrupt E2:E3 ligase complexes such as UBC13:TRAF6, UBCH5c:TRAF6, 
and UBC13:cIAP1. This leads to K48-linked polyubiquitination of UBC13 and 
UBCH5c targeting the E2s for proteasomal degradation, thereby generally affecting 
global K63-linked polyubiquitination (Figure 5) (Shembade et al., 2010). In addition, 
A20 can interact with K63-linked and linear chains through ZnF4 and ZnF7. By 
competitively binding to these chains, A20 is thought to inhibit proper assembly of 
ubiquitin-dependent signaling platforms (Figure 5) (Bosanac et al., 2010; Verhelst et 
al., 2012). Finally, A20 has also been implicated in targeting TRAF2 for lysosomal 
degradation (Li et al., 2009). In conclusion, A20 regulates multiple aspects of 
ubiquitin-dependent signaling to NF-κB by its diverse catalytic and non-catalytic 
functions. 
A20 was initially characterized as a protein inhibiting TNF-induced cell death 
(Opipari et al., 1992). However, the function of A20 in the regulation of apoptosis 
remains controversial and seems to be stimulus and cell type specific. On the one 
hand, A20 was shown to have anti-apoptotic functions in response to death receptor 
engagement (Jin et al., 2009; Lee et al., 2000; Opipari et al., 1992). In this context, 
one potential mechanism could be the regulation of K63-linked polyubiquitin and 
thereby activation of caspase-8 by A20 (Jin et al., 2009). On the other hand, pro-
apoptotic functions of A20 seem to be predominantly mediated by inhibiting NF-κB-
dependent expression of pro-survival Bcl-2 family members (Kool et al., 2011; 
Tavares et al., 2010). In addition, A20 has been shown to regulate the non-canonical 
TGFβ pathway, Wnt signaling, the antiviral interferon regulated factor (IRF)3 and 
IRF7 pathways and autophagy (Jung et al., 2013; Maelfait et al., 2012; Saitoh et al., 
2005; Shao et al., 2013; Shi and Kehrl, 2010). 
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4.2.7. Cell Type-Specific Functions of A20  
 
The multiorgan inflammation and perinatal lethality of A20-deficient mice impeded 
studying the role of A20 in adult mice during immune homeostasis and disease 
pathology (Lee et al., 2000). Hence, several conditional alleles were generated 
allowing A20 deletion in a temporal and lineage-specific fashion (Hövelmeyer et al., 
2011; Tavares et al., 2010; Vereecke et al., 2010). Loss of A20 in macrophages and 
granulocytes (LysM-Cre A20F/F) caused MyD88-dependent spontaneous polyarthritis 
connected to increased systemic pro-inflammatory cytokine levels such as IL-6 
(Matmati et al., 2011). A20 ablation in DCs (CD11c-Cre A20F/F) led to their 
spontaneous activation, excessive pro-inflammatory cytokine production and 
profound disturbances of immune homeostasis (Hammer et al., 2011; Kool et al., 
2011). Interestingly, two groups independently generated DC-specific A20 knock-out 
mice with remarkable differences regarding the resulting disease pathologies. One 
strain spontaneously developed MyD88-dependent colitis associated with arthritis 
reminiscent of human inflammatory bowel disease (Hammer et al., 2011). In contrast, 
the other strain developed systemic lupus erythematosus (SLE)-like DNA-specific 
autoantibodies accompanied by glomerulonephritis (Kool et al., 2011). A20-deficient 
B cells (CD19-Cre A20F/F) exhibited enhance NF-κB activation in response to various 
stimuli, produced higher levels of pro-inflammatory cytokines such as IL-6 and 
caused an autoimmune syndrome characterized by the presence of class-switched 
tissue-specific autoantibodies (Chu et al., 2011; Hövelmeyer et al., 2011; Tavares et 
al., 2010). Loss of A20 in intestinal epithelial cells (Villin-Cre A20F/F) increased 
susceptibility to TNF-induced cell death and inflammation in addition to rendering 
mice hypersensitive to experimental colitis (Vereecke et al., 2010). Epidermis-specific 
A20 deletion (K14-Cre A20F/F) did not cause spontaneous skin inflammation, 
however, mice showed keratinocyte hyperproliferation and ectodermal abnormalities 
(Lippens et al., 2011). These studies revealed the various cell type-specific functions 
of A20 highlighting its critical role for the prevention of inflammation and 
autoimmunity.  
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4.2.8. A20/TNFAIP3 in Human Diseases  
 
Human genome wide association studies (GWASs) have linked germline single 
nucleotide polymorphisms (SNPs) in human TNFAIP3 (the gene encoding for A20) 
with susceptibility to human inflammatory and autoimmune diseases, including 
rheumatoid arthritis, SLE, type I diabetes, Crohn’s disease, coeliac disease, coronary 
artery disease, psoriasis and systemic sclerosis (Ma and Malynn, 2012; Vereecke et 
al., 2009). Most of the SNPs are located outside the coding region, suggesting that 
they might interfere with A20 expression. Indeed, an SLE-associated SNP within a 
putative 3’ enhancer reduces A20 expression (Adrianto et al., 2011). So far only two 
SNPs within the TNFAIP3 coding region have been reported, one of which is an SLE-
associated SNP resulting in a phenylalanine-to-cysteine change within the DUB 
domain that reduces A20 function (Musone et al., 2008). As A20 regulates cellular 
activation in a gene-dose-dependent fashion, reducing its expression or function 
might have physiological relevance (Chu et al., 2011).  
In addition, mutations and deletions in TNFAIP3 have been identified in 
several human B lymphomas including Hodgkin’s lymphoma, mucosa-associated 
lymphoid tissue-type lymphoma, diffuse large B cell lymphoma and primary 
mediastinal B cell lymphoma (Malynn and Ma, 2009). These mutations result in the 
introduction of stop codons, frame shifts or amino-acid substitutions that might affect 
A20 function and/or stability (Malynn and Ma, 2009). Reconstitution of A20 in in A20-
null lymphoma cell lines suppresses NF-κB activation leading to the induction of 
apoptosis and growth arrest, indicating a tumor suppressor role (Compagno et al., 
2009). Similar GWASs have identified TNIP1 (the gene encoding for the A20 binding 
partner ABIN1) as a susceptibility locus for autoimmune diseases such as psoriatic 
arthritis and SLE (Ma and Malynn, 2012), in addition to asthma (Li et al., 2012). 
Furthermore, somatic mutations in TNIP1 were identified in human lymphomas, 
further suggesting a functional relationship between A20 and ABIN1 (Ma and Malynn, 
2012).    
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5. Aims of the Thesis 
 
Mast cells have long been recognized as key effector cells in IgE-dependent 
anaphylactic reactions, but were also implicated in playing a central role in several 
aspects of inflammatory and autoimmune diseases. However, concepts on these 
pathological mast cell functions were primarily based on studies employing Kit 
mutant mast cell-deficient mice. These mice suffer from various abnormalities 
besides the loss of mast cells and, hence, many of the initially obtained results were 
challenged later on. Furthermore, the signals mast cells receive under physiological 
and pathological conditions are poorly defined. Additionally, mast cell-deficient 
mouse models are not suited to study the function of specific genes during mast cell 
development, homeostasis and function. Hence, novel mouse models that allow to 
study the role of mast cells using gain-of-function approaches and to inducibly 
manipulate their genome are urgently required. 
 
In the course of this thesis, I experimentally addressed the following three critical 
points: 
 
1. Dissecting the consequences of A20 deficiency on mast cell activation 
during physiology and pathology to generate a novel mouse model for 
hyperactive mast cells (Publication I). 
2. Investigating the role of A20 during in vitro B cell activation (Publication II). 
3. Characterizing the KitCreERT2 mouse strain as a novel genetic tool for 
inducible conditional gene targeting in and ablation of mast cells 
(Publication III). 
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6. Abstracts of Publications  
 
For copyright reasons, full versions of the publications are not included in the online 
version of this thesis. Please follow the links below the abstracts to download the pdf 
files directly from the publisher’s website. 
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 Publication I 6.1.
 
A20-Deficient Mast Cells Exacerbate Inflammatory Responses in Vivo. 
 
Heger K.*, Fierens K.*, Vahl J.C., Aszodi A., Peschke K., Schenten D., Hammad H., 
Beyaert R., Saur D., van Loo G., Roers A., Lambrecht B.N., Kool M. and Schmidt-
Supprian M. (2014) PLoS Biol 12: e1001762. *equal contribution 
 
Mast cells are implicated in the pathogenesis of inflammatory and autoimmune 
diseases. However, this notion based on studies in mast cell-deficient mice is 
controversial. We therefore established an in vivo model for hyperactive mast cells by 
specifically ablating the NF-κB negative feedback regulator A20. While A20 
deficiency did not affect mast cell degranulation, it resulted in amplified pro-
inflammatory responses downstream of IgE/FcεRI, TLRs, IL-1R and IL-33R. As a 
consequence house dust mite- and IL-33-driven lung inflammation, late phase 
cutaneous anaphylaxis and collagen-induced arthritis were aggravated, in contrast to 
experimental autoimmune encephalomyelitis and immediate anaphylaxis. Our results 
provide in vivo evidence that hyperactive mast cells can exacerbate inflammatory 
disorders and define diseases that might benefit from therapeutic intervention with 
mast cell function. 
 
Full text 
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 Publication II 6.2.
 
B cells lacking the tumor suppressor TNFAIP3/A20 display impaired 
differentiation and hyperactivation and cause inflammation and 
autoimmunity in aged mice. 
 
Chu Y., Vahl J.C., Kumar D., Heger K., Bertossi A., Wójtowicz E., Soberon V., 
Schenten D., Mack B., Reutelshöfer M., Beyaert R., Amann K., van Loo G. and 
Schmidt-Supprian M. (2011) Blood 117: 2227–2236. 
 
The ubiquitin-editing enzyme A20/TNFAIP3 is essential for controlling signals 
inducing the activation of nuclear factor-κB transcription factors. Polymorphisms and 
mutations in the TNFAIP3 gene are linked to various human autoimmune conditions, 
and inactivation of A20 is a frequent event in human B-cell lymphomas characterized 
by constitutive nuclear factor-κB activity. Through B cell-specific ablation in the 
mouse, we show here that A20 is required for the normal differentiation of the 
marginal zone B and B1 cell subsets. However, loss of A20 in B cells lowers their 
activation threshold and enhances proliferation and survival in a gene-dose-
dependent fashion. Through the expression of proinflammatory cytokines, most 
notably interleukin-6, A20-deficient B cells trigger a progressive inflammatory 
reaction in naive mice characterized by the expansion of myeloid cells, effector-type 
T cells, and regulatory T cells. This culminates in old mice in an autoimmune 
syndrome characterized by splenomegaly, plasma cell hyperplasia, and the presence 
of class-switched, tissue-specific autoantibodies. 
 
Full text 
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 Publication III 6.3.
 
CreERT2 expression from within the c-Kit gene locus allows efficient 
inducible gene targeting in and ablation of mast cells. 
 
Heger K., Seidler B., Vahl J.C., Schwartz C., Kober M., Klein S., Voehringer D., Saur 
D. and Schmidt-Supprian M. (2014) Eur J Immunol 44: 296–306.  
 
Mast cells are abundantly situated at contact sites between the body and its 
environment, such as the skin and, especially during certain immune responses, at 
mucosal surfaces. They mediate allergic reactions and degrade toxins as well as 
venoms. However, their roles during innate and adaptive immune responses remain 
controversial and it is likely that major functions remain to be discovered. Recent 
developments in mast cell-specific conditional gene targeting in the mouse promise 
to enhance our understanding of these fascinating cells. To complete the genetic 
toolbox to study mast cell development, homeostasis and function, it is imperative to 
inducibly manipulate their gene expression. Here, we report the generation of a novel 
knock-in mouse line expressing a tamoxifen-inducible version of the Cre 
recombinase from within the endogenous c-Kit locus. We demonstrate highly efficient 
and specific inducible expression of a fluorescent reporter protein in mast cells both 
in vivo and in vitro. Furthermore, induction of diphtheria toxin A expression allowed 
selective and efficient ablation of mast cells at various anatomical locations, while 
other hematopoietic cells remain unaffected. This novel mouse strain will hence be 
very valuable to study mast cell homeostasis and how specific genes influence their 
functions in physiology and pathology. 
 
Full text 
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7. Discussion 
 
Despite their discovery more than 130 years ago and extensive research during the 
last decades, mast cells are still one of the most enigmatic cell types of the immune 
system, and their precise physiological and pathological functions remain 
controversial. Studies in Kit mutant mast cell-deficient mice have been instrumental in 
assessing their in vivo role. However, in the context of inflammatory and autoimmune 
disorders these mouse strains have yielded ambiguous and contradicting results, 
presumably due to additional effects of c-Kit deficiency. Moreover, the role of specific 
genes during mast cell development, homeostasis and function are poorly defined. 
Hence, novel genetic tools to evaluate the consequences of mast cell deficiency, to 
activate or inactivate genes in a mast cell-specific and inducible fashion are urgently 
required. Therefore, through mast cell-specific A20 deficiency, I established the first 
gain-of-function model for hyperactive mast cells with overshooting inflammatory 
responses. Moreover, I characterized the first mouse strain that allows inducible 
conditional gene targeting in and ablation of mast cells. My analyses of these novel 
mouse strains yielded important insights into mast cell biology and pathology and 
promise to enhance our understanding of these puzzling cells. 
 
 
 Generation of an in Vivo Mouse Model for 7.1.
Hyperactive Mast Cells  
7.1.1. A20 Selectively Regulates Inflammatory But Not Anaphylactic 
Mast Cell Responses  
 
When work on this study commenced, in vivo analyses of mast cell functions were 
almost entirely based on a single experimental system, namely the use of mast cell-
deficient KitW/Wv and KitW-sh/W-sh mice and their selective reconstitution with cultured 
mast cells (Grimbaldeston et al., 2005; Nakano et al., 1985). However, conflicting 
results were obtained regarding the impact of mast cells on inflammatory and 
autoimmune diseases (Rodewald and Feyerabend, 2012). Hence, I reasoned that a 
genetic gain-of-function in vivo model would allow addressing these important 
questions from a different angle. In addition, this approach would circumvent potential 
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cellular compensation artifacts caused by the constitutive absence of mast cells. 
Moreover, enhancing mast cell functions would help to define their maximal impact in 
a given disease context.  
 Genetic studies demonstrated that the ubiquitin-editing enzyme and NF-κB 
negative feedback regulator A20 is crucial for the prevention of inflammation in mice 
(Lee et al., 2000). Moreover, polymorphisms in the A20 gene locus were linked to 
several human inflammatory and autoimmune diseases (Ma and Malynn, 2012; 
Vereecke et al., 2009). Hence, ablation of A20 was a promising and physiologically 
relevant method to generate hyperactive mast cells. In addition, this approach would 
allow dissecting the nature of stimuli mast cells sense under steady-state conditions 
and how they are activated during pathologies. When I started working on this thesis, 
A20 had been shown to restrict signal transduction triggered by TLRs, the IL-1R, 
TNFRs and intracellular NOD2 receptors (Boone et al., 2004; Hitotsumatsu et al., 
2008; Lee et al., 2000; Wertz et al., 2004), however, little was known about its cell 
type-specific functions. Hence, I first investigated the impact of A20 deficiency on 
mast cell functions in vitro. By comparing (at the time) known A20 targets to 
components used in mast cells for signal transduction, I hypothesized that, in 
addition to known pathways, A20 might also restrict NF-κB activation downstream of 
the IgE/FcεRI module and the IL-33R.  
This hypothesis was based on the following considerations. Firstly, in mast 
cells, Bcl-10 and MALT1 were identified as essential signaling components mediating 
NF-κB activation upon FcεRI crosslinking (Klemm et al., 2006). Interestingly, in T 
cells MALT1 was shown to interact with TRAF6, thereby stimulating its E3 ligase 
activity resulting in K63-linked polyubiquitin chain assembly and activation of the IKK 
complex (Sun et al., 2004). Secondly, upon stimulation with IL-33, TRAF6 gets 
recruited to the IL-33R and is essential for signal transduction to NF-κB (Funakoshi-
Tago et al., 2008; Schmitz et al., 2005). Finally, A20 was shown to terminate NF-κB 
responses by removing K63-linked polyubiquitin chains from TRAF6 (Boone et al., 
2004; Lin et al., 2008) and from MALT1 (Duwel et al., 2009). 
Confirming my initial hypothesis, A20 indeed restricted NF-κB activation in 
mast cells upon crosslinking of the FcεRI and stimulation with IL-33 (Publication I). 
As a consequence pro-inflammatory cytokine production and activation marker 
expression was dramatically enhanced in A20-deficient mast cells in comparison to 
control cells, highlighting an important and hitherto unrecognized role of A20 in these 
signaling pathways. In addition, I confirmed the function of A20 in the regulation of 
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pro-inflammatory signals triggered by IL-1β and TLR ligands (Publication I). Similarly, 
also in B cells A20 specifically regulated NF-κB activation and pro-inflammatory 
cytokine production upon engagement of the B cell receptor, CD40 and TLRs 
(Publication II).  
Although A20 deficiency exaggerated NF-κB activation, it did not affect 
degranulation induced by crosslinking of the FcεRI (Publication I). The latter event is 
not spontaneous and requires the concerted action of several proteins (Lorentz et al., 
2012). The most prominent task is fulfilled by soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) proteins, which form a ternary SNARE 
complex to bring vesicle and plasma membranes in juxtaposition (Lorentz et al., 
2012). Phosphorylation of the target membrane SNARE protein SNAP-23 was shown 
to be critically involved in the regulation of degranulation (Hepp et al., 2005), 
however, which kinase fulfills this task is a matter of debate: it has been proposed 
that PKCβ regulates degranulation by the direct phosphorylation of SNAP-23 (Hepp 
et al., 2005), but later genetic studies demonstrated the essential and non-redundant 
function of IKK2 in this process, apart from phosphorylating IκB proteins and thus 
independent of NF-κB activation (Suzuki and Verma, 2008). However, NF-κB might 
control degranulation on a transcriptional level by regulating the expression of store-
operated calcium channels, which prolong and potentiate the initial cytosolic Ca2+ 
response upon FcεRI engagement (Eylenstein et al., 2012; Vig et al., 2008).  
A20 was thought to regulate receptor proximal ubiquitination events upstream 
of the IKK complex and hence NF-κB transcription factor activation (Wertz and Dixit, 
2010). Therefore, it was possible that A20-deficieny would have an impact on 
degranulation by both NF-κB-independent and NF-κB–dependent mechanisms. I 
demonstrated that loss of A20 specifically in mast cells did not affect immediate local 
or systemic anaphylaxis events (Publication I) that are dependent on mast cell 
degranulation (Feyerabend et al., 2011; Klemm et al., 2006; Sawaguchi et al., 2012). 
In vitro studies confirmed that the loss of A20 had no impact on mast cell 
degranulation (Publication I). This indicated that A20 regulates signaling events after 
bifurcation of the pathway leading to either degranulation or NF-κB activation, 
presumably at the level or downstream of Bcl-10, MALT1 or TRAF6. This is in line 
with recent observations demonstrating that degranulation was unaffected in Bcl-10-, 
MALT1- and TRAF6-deficient mast cells, whereas NF-κB activation was severely 
compromised (Klemm et al., 2006; Yang et al., 2008).  
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At this stage, I can only speculate why IKK2 deficiency affected 
degranulation, although loss of the further-upstream signaling components A20, 
Bcl-10, MALT1 and TRAF6 did not (Publication I) (Klemm et al., 2006; Suzuki and 
Verma, 2008; Yang et al., 2008). Suzuki and Verma generated mast cells from the 
fetal liver in order to circumvent the early lethality of IKK2-deficient mice (Suzuki and 
Verma, 2008). Hence, both differentiation and expansion of fetal liver-derived mast 
cells proceeded in the complete absence of IKK2. This could affect their functional 
maturation and thereby indirectly influenced their degranulation response. Fittingly, 
pharmacological IKK2 inhibition in mature mast cells had no effect on degranulation 
(Peng et al., 2005). In order to avoid such potential biases through effects of gene 
deficiency during mast cell development in vitro, I employed the novel KitCreERT2 
transgene (Publication III) to delete conditional A20 and MyD88 alleles in mature 
mast cells after differentiation (Publication I). Future similar studies using conditional 
or inducible ablation of IKK2 in mature mast cells will be essential to further clarify the 
role of IKK2 during degranulation and in anaphylactic responses.  
Collectively, my results indicate that A20 selectively terminates NF-κB 
activation and thus pro-inflammatory mast cell responses without affecting 
degranulation or anaphylactic reactions. This feature has important implications for 
mast cell biology, as it allows a full-blown anaphylactic response to antigen in a mast 
cell whose pro-inflammatory signaling is impaired by high levels of A20 due to 
previous recognition of pathogens or alarmins. It furthermore indicates that, in a 
clinical setting, anaphylactic responses can neither be aggravated nor treated by 
modulating A20 function. 
 
7.1.2. Despite Their Pronounced Hyperactivity, A20-Deficient Mast 
Cells Do Not Cause Overt Spontaneous Inflammation 
 
The potent anti-inflammatory functions of A20 were clearly demonstrated by the 
generation of mice completely deficient for A20, which suffer from severe multiorgan 
inflammation and cachexia leading to perinatal lethality (Lee et al., 2000). 
Subsequent studies indicated that this phenotype is caused by exacerbated MyD88-
dependent TLR signals in response to commensal bacteria, which trigger 
spontaneous detrimental myeloid cell activation (Turer et al., 2008). Fittingly, loss of 
A20 specifically in myeloid and dendritic cells disturbed immune homeostasis and 
resulted in spontaneous MyD88-dependent pathologies (Hammer et al., 2011; 
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Matmati et al., 2011). Similar to many tissue-resident myeloid cell populations, mast 
cells express various TLRs and are located at the host-environment border where 
commensals are frequently encountered (Abraham and St John, 2010). In addition, 
overall mast cell numbers are estimated to be equal to the total number of 
splenocytes (Sayed et al., 2008). Hence, it was surprising to observe that mice 
containing A20-deficient mast cells (Mcpt5Cre A20F/F) did not suffer from overt 
spontaneous inflammation (Publication I). This indicates that mast cells might have 
developed additional control mechanisms, which are not shared with other myeloid 
cells, and hence might be intrinsically less prone to initiate inflammation. 
Alternatively, although A20 deficiency caused dramatically enhanced NF-κB 
responses to several physiologically relevant stimuli in vitro (Publication I), the 
signals mast cells receive in vivo might be rather weak.  
Intriguingly, mast cells cannot be fully activated by TLR4-dependet stimuli. 
This is due to a defect in TRIF signaling that reduces pro-inflammatory cytokine 
production and precludes an anti-viral interferon response (Keck et al., 2011). 
Moreover, mast cells lack expression of the TLR4 coreceptor CD14 and hence 
depend on the presence of soluble CD14 to efficiently respond to the bacterial cell 
wall component LPS (McCurdy et al., 2001). Fittingly, high LPS concentrations had to 
be used in vitro to activate mast cells (Publication I). As commensal bacteria under 
steady-state conditions are recognized by TLRs (Rakoff-Nahoum et al., 2004), 
diminished TLR-dependent mast cell activation could at least in part account for the 
lack of overt spontaneous inflammation in mice with mast cell-specific A20 
deficiency. These observations suggest that functional inactivation of A20 has the 
most dramatic consequences in cells capable of high affinity LPS recognition, such 
as myeloid and dendritic cells (Hammer et al., 2011; Kool et al., 2011; Matmati et al., 
2011), and has less impact in cells with low-affinity LPS receptors such as B cells 
and mast cells (Publication I and II) (Tavares et al., 2010). This implies that, of the 
many MyD88-dependent receptors, TLR4 might be the main receptor driving 
spontaneous inflammation caused by A20-deficiency. Given the tremendous impact 
of diminished A20 function in human inflammatory and autoimmune diseases, this 
hypothesis warrants further investigation. It furthermore suggests that interference 
with TLR4 pattern recognition might allow translation into clinical applications to treat 
inflammatory diseases that are linked to SNPs in the A20 gene locus.  
 In addition, my in vitro experiments showed that mast cells are more 
efficiently activated by IL-33 than LPS (Publication I). Mast cells can sense IL-33 by 
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constitutively expressing the IL-33R α-chain (ST2) (Moritz et al., 1998). In fact, under 
steady-state conditions mast cells are the main cell type in the peritoneal and pleural 
cavities showing high ST2 cell surface levels (K. Heger and M. Schmidt-Supprian 
unpublished observations) (Enoksson et al., 2013). IL-33 is expressed by structural 
cells and is thought to be released upon cell injury, trauma or infection (Lüthi et al., 
2009; Moussion et al., 2008). Indeed, mast cells can be activated in vitro by necrotic 
cells and, therefore, are considered to be the link between cell injury and the initiation 
of inflammation (Enoksson et al., 2011; Lunderius-Andersson et al., 2012). However, 
although IL-33-deficient mice have recently been reported it is unclear to what extent 
IL-33 is released under steady-state conditions and, hence, could be sensed by mast 
cells (Oboki et al., 2010). A20-deficient mast cells showed dramatically enhanced 
NF-κB activation and pro-inflammatory cytokine production upon IL-33 stimulation in 
vitro (Publication I). Thus, the absence of overt spontaneous mast cell activation and 
inflammation in vivo might indicate that only small amounts of IL-33 are released 
under physiological conditions. This might be of particular importance as upon 
liberation IL-33 can potently induce inflammation in addition to Th2 responses (Palm 
et al., 2013; Schmitz et al., 2005), which could cause sensitization towards seemingly 
harmless non-self antigens leading to detrimental allergic diseases (Galli and Tsai, 
2012).  
Although A20-deficient mast cells did not cause overt inflammation in vivo 
they displayed a pre-activated or poised state as indicated by the enhanced 
production of pro-inflammatory cytokines (Publication I). Moreover, in 
Mcpt5Cre A20F/F mice, mast cell numbers were enhanced due to an overall increase 
in peritoneal cellularity, and mice developed minor splenomegaly with mild 
expansions of myeloid cell subsets and T cells with an effector-like phenotype 
(Publication I and K. Heger and M. Schmidt-Supprian unpublished observations). All 
of these processes depended on the adapter MyD88 (Publication I), suggesting that 
mast cells - similarly to other immune cells - constantly receive some, but apparently 
mild signals via one or more MyD88-dependent receptors that are held in check by 
A20, such as TLRs, the IL-1R, the IL-18R or the IL-33R (Hammer et al., 2011; 
Matmati et al., 2011). Future crosses of Mcpt5Cre A20F/F mice onto an IL-33-deficient 
background or treatment with broad-spectrum antibiotics would clarify the 
contribution of IL-33 or the commensal microbiota to these processes and define the 
nature of stimuli that mast cells sense under physiological conditions. 
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Collectively, my results indicate that, although in vitro A20 deficiency causes 
dramatically enhanced NF-κB activation in response to various physiologically 
relevant stimuli, under steady-state conditions mast cell-specific A20 deficiency does 
not cause overt spontaneous inflammation but induces a pre-activated or poised 
state.  
 
7.1.3. Dissecting the Role of Mast Cells in Mouse Models for Human 
Inflammatory and Autoimmune Diseases through an in Vivo 
Gain-of-Function Approach 
 
Mast cells have been implicated as important effector cells in diverse physiological 
and pathological conditions, including in mouse models of asthma, multiple sclerosis 
and rheumatoid arthritis (Lee et al., 2002; Secor et al., 2000; Williams and Galli, 
2000). However, this notion was based on mast cell-deficient KitW/Wv and KitW-sh/W-sh 
mice, which suffer from various additional defects within and outside of the immune 
system (Rodewald and Feyerabend, 2012). Moreover, using these mice represents a 
loss-of-function approach that describes the consequences of absent function, which 
is not always inversely correlated with excessive function. This is particularly evident 
when looking at DCs, as both their ablation and their persistent activation resulted in 
spontaneous autoimmune pathologies (Hammer et al., 2011; Kool et al., 2011; 
Ohnmacht et al., 2009). I found that A20 selectively regulated pro-inflammatory 
NF-κB-dependent but not anaphylactic reactions and caused pronounced mast cell 
hyperactivation (Publication I). Hence, I sought to reassess their innate inflammatory 
properties in the context of allergic, inflammatory and autoimmune diseases by using 
a novel gain-of function approach - inactivation of A20 specifically in mast cells. Loss 
of A20 in mast cells in Mcpt5Cre A20F/F mice exacerbated innate forms of asthma 
elicited by the administration of house dust mite extracts or following sensitization to 
the model allergen ovalbumin under mild conditions (Publication I). These results 
correlate with existing data from various mast cell-deficient mouse models that 
showed reduced symptoms and point to a crucial role of mast cells in asthma 
pathogenesis (Nakae et al., 2007; Sawaguchi et al., 2012; Williams and Galli, 2000). 
Mcpt5Cre A20F/F mice additionally showed early onset and exacerbated disease 
symptoms during collagen-induced arthritis (CIA), a mouse model for rheumatoid 
arthritis (Publication I).  
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In this context, it is interesting to note that various studies have suggested a 
pathogenic role for IL-33 in both asthma and rheumatoid arthritis (Ohno et al., 2012; 
Palmer and Gabay, 2011). Additionally, it was proposed that during the course of 
arthritis, IL-33 could promote joint inflammation at least in part by the activation of 
mast cells (Xu et al., 2008). This is in line with my findings that loss of A20 in mast 
cells exacerbates IL-33-induced NF-κB activation and pro-inflammatory cytokine 
production (Publication I). Hence, augmented responses to IL-33 might lead to locally 
restricted inflammation during arthritis pathology. In this scenario, enhanced IL-33-
dependent pro-inflammatory cytokine production by A20-deficient mast cells might in 
turn cause greater IL-33 expression in synovial fibroblasts. Its subsequent release 
could signal back to mast cells leading to paracrine auto-amplification and a 
detrimental feed-forward loop. This scenario is supported by the fact that mast cell-
specific MyD88 deficiency ameliorates arthritis onset as well as disease symptoms 
(Publication I). 
In addition to arthritis, IL-33-dependent paracrine feed-forward loops might 
also play a central role in various other inflammatory diseases that have an IL-33 
component and are associated with polymorphism in the A20 gene locus, such as 
psoriasis, systemic sclerosis and inflammatory bowel disease (Ma and Malynn, 2012; 
Palmer and Gabay, 2011; Vereecke et al., 2009). Interestingly, mast cells have also 
been implicated in these pathologies (Chichlowski et al., 2010; Eklund, 2007; 
Harvima et al., 2008). Hence, dissecting mast cell-specific A20-deficieny in relevant 
mouse models might yield important insights into the etiology and progression of 
these diseases. 
My results are in apparent discrepancy to a study showing that the loss of 
mast cells in KitW-sh/W-sh mice did not significantly alter CIA disease outcome (Pitman 
et al., 2011). However, studying the function of mast cells by their absence in 
KitW-sh/W-sh mice bears the inherent caveat that other cell types could functionally 
compensate for their loss. This has already been demonstrated during the early 
innate response to haptens, in which neutrophils take over the function of mast cells 
in the context of the prominent myelodysplasia seen in KitW-sh/W-sh mice (Dudeck et al., 
2011). Hence, the depletion of neutrophils would clarify their contribution in KitW-sh/W-sh 
mice during CIA.  
In contrast to airway and joint inflammation, A20-deficient mast cells did not 
worsen EAE symptoms (Publication I), possibly because initiation and progression of 
this disease is IL-33 independent (Oboki et al., 2010). These results do not 
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completely exclude a role for mast cells in this model. Firstly, deletion of A20 is 
limited to CTMCs while MMCs remain unaffected and, secondly, A20 deficiency 
selectively influences pro-inflammatory NF-κB-driven responses without affecting 
degranulation. Hence, general activation of mucosal in addition to connective tissue 
mast cells might have different effects than seen in Mcpt5Cre A20F/F mice. 
Nonetheless, my results clearly show that enhancing the pro-inflammatory reactions 
of CTMCs has no influence on MOG peptide-induced central nervous system 
inflammation. These results are in contrast to the apparently well-documented role of 
mast cells in EAE pathology (Sayed et al., 2008; Secor et al., 2000). However, this 
notion is primarily based on a single genetic tool, namely the use of mast cell-
deficient KitW/Wv mice. In recent years the use of mast-cell-deficient KitW-sh/W-sh mice 
has become more and more popular as this strain shows milder Kit-dependent 
developmental abnormalities than KitW/Wv mice (Grimbaldeston et al., 2005). 
Comparing mast cell-deficient KitW/Wv and KitW-sh/W-sh mice yielded conflicting 
data regarding their contribution to autoimmune pathologies. Surprisingly, KitW-sh/W-sh 
mice showed even earlier onset and developed exacerbated EAE symptoms (Li et 
al., 2011; Piconese et al., 2011). Furthermore, depending on the immunization 
protocol, EAE disease outcome can be modulated in KitW/Wv mice from protective to 
even exacerbating (Piconese et al., 2011) and two recent reports failed to confirm 
that KitW/Wv mice are protected from EAE (Bennett et al., 2009; Feyerabend et al., 
2011). It is worth noting that all of these results were obtained in the absence of mast 
cells and fail to clarify whether or not mast cells participate in EAE disease pathology. 
Moreover, my results using a gain-of-function approach by mast cell-specific ablation 
of A20 (Publication I) and novel Kit-independent mast cell-deficient mice have failed 
to corroborate a contribution of mast cells to EAE (Feyerabend et al., 2011). 
Collectively, these results do not support a major function of mast cells in the 
pathogenesis of EAE. 
In addition to playing central pathological roles in autoimmune diseases, 
many reports assign to mast cells various additional effector and regulatory functions 
in immune responses against viral (Aoki et al., 2013), bacterial (Echtenacher et al., 
1996; Malaviya et al., 1996), and parasitic infections (Ha et al., 1983), in 
cardiovascular disorders (Sun et al., 2007), obesity and diabetes (Liu et al., 2009), in 
malignant diseases and angiogenesis (Coussens et al., 1999), in contact 
hypersensitivity in the skin (Grimbaldeston et al., 2007) and the recognition of cell 
injury (Enoksson et al., 2011; 2013). However, most in vivo evidence for these mast 
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cell functions is also based on Kit mutant mast cell-deficient mice. Similar to 
discrepant results on the role of mast cells in autoimmune diseases, studies using 
novel Kit-independent strains failed to confirm some of the initial results regarding 
contact hypersensitivity (Dudeck et al., 2011; Otsuka et al., 2011), wound healing 
(Antsiferova et al., 2013) and skin carcinogenesis (Antsiferova et al., 2013). These 
fundamental discrepancies indicate that using Kit mutant mice and the mast cell 
reconstitution approaches can generate misleading results and might lead to false 
interpretations. Therefore, it will be essential to readdress central mast cell findings 
using novel genetic mouse models. My analysis on the consequences of 
A20-deficiency in mast cells yielded specific results with regard to different disease 
models, specifically, exacerbation of innate forms of asthma and CIA in contrast to no 
effect on EAE. This shows that the Mcpt5Cre A20F/F strain will be a valuable and 
informative gain-of-function tool to complement loss-of-function studies. This should 
be especially true under conditions where mast cells are presumably activated 
through their IL-33R or TLRs such as tumor development, the initiation of Th2 
responses, and the detection of tissue damage or microbial infections. 
In summary, my data demonstrate that loss of A20 specifically in mast cells 
provides a novel genetic model system to study their pro-inflammatory properties in a 
gain-of-function approach. These hyperactive mast cells exacerbated allergic airway 
and skin responses, as well as autoimmune joint inflammation pointing to an 
important contribution of mast cells in these pathologies. 
 
 
 Inducible Conditional Gene Targeting in Mast Cells 7.2.
Allows Studying their Differentiation and Cellular 
Maintenance  
 
When I started my thesis, mast cell-specific conditional gene targeting was in its early 
stages and the functions of specific genes were studied by the reconstitution of Kit 
mutant mice with cultured mast cells derived from mutant or transgenic bone marrow 
(Tsai et al., 2005). However, depending on the route of administration, reconstitution 
may not reach physiological mast cell levels or their number might sometimes even 
be higher than normal (Grimbaldeston et al., 2005; Nakano et al., 1985). In addition, 
the anatomical distribution and phenotype of the adoptively transferred mast cells 
might not be identical to their natural counterparts (Rodewald and Feyerabend, 
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2012). Therefore, using this mast cell reconstitution approach does not allow faithful 
investigation of the function of specific genes during bona fide mast cell development, 
homeostasis and function. Recent advances in gene targeting and transgenesis led 
to the generation of novel mouse strains that constitutively express the Cre 
recombinase and, thus, allow mast-cell-specific conditional gene targeting to varying 
degrees of efficiency and specificity (Feyerabend et al., 2011; Furumoto et al., 2011; 
Müsch et al., 2008; Scholten et al., 2008). However, if the loss of specific genes 
impedes or affects mast cell development, temporal control of Cre activity is required 
to delete genes in mature mast cells. Furthermore, acute gene deletion is essential 
for the validation of potential drug targets and the avoidance of molecular and cellular 
compensation mechanism. Similarly, acute gene modification is required for in vivo 
cell-fate tracking, a powerful genetic approach to study cellular differentiation. 
The group of Dr. Dieter Saur has generated a knock-in mouse strain 
expressing a tamoxifen-inducible version of the Cre recombinase from within the 
endogenous c-Kit locus (Klein et al., 2013). Since Cre efficiency is relative to its 
expression strength (Araki et al., 1997; Schmidt-Supprian et al., 2007) and mast cells 
within the hematopoietic system exhibit very high c-Kit expression (Publication III), I 
reasoned that this mouse strain should allow efficient recombination of conditional 
(loxP-flanked) alleles in mast cells. Indeed, the use of a fluorescent Cre recombinase 
activity reporter (R26-StopFYFP) revealed high mast cell specificity and efficiency and 
gave important insights into mast cell development.  
Mast cells are thought to share a common progenitor with basophils in the 
spleen (basophil and mast cell progenitor, BMCP) (Arinobu et al., 2005). However, 
although more than 90% of mature dermal and peritoneal mast cells, and nearly 16% 
of BMCPs in tamoxifen-fed KitCreERT2/+R26-StopFYFP animals expressed YFP, 
recombination in basophils was minimal (Publication III). This indicates that, under 
physiological conditions in the steady-state, YFP-positive BMCPs do not significantly 
differentiate into basophils. My results hence challenge the validity of BMCPs as 
authentic bipotential basophil and mast cell progenitors. This is in line with two recent 
publications demonstrating a greater tendency of BMCPs to develop into mast cells 
in vitro (Mukai et al., 2012; Qi et al., 2013). Further pulse-labeling experiments 
demonstrated that 8 weeks after cessations of tamoxifen, still more then 90% of mast 
cells expressed YFP (Publication III). These results indicate a very slow turnover of 
mature mast cells and regeneration from unaffected progenitors. To the best of my 
knowledge, this is the first direct genetic evidence that mature mast cells are indeed 
Discussion 
 
50 
very long-lived. Previous attempts to study mast cell turnover by radioactive 
thymidine labeling provided half-life estimates ranging from days up to years 
(Kiernan, 1979; Walker, 1961). Although the exact reasons for mast cell longevity are 
presently unclear, it has been speculated that mast cells might be able to modulate 
the content of their granules in response to certain stimuli, a process that could be 
considered to be a form of immunological memory (Abraham and St John, 2010). 
Moreover, I found that 4 weeks after ablation of mast cells by DTA expression 
(KitCreERT2/+R26-GFPStopFDTA), very few mast cells had regenerated from unaffected 
progenitors (Publication III). These results are in full agreement with a recent study 
by Dudeck and colleagues who demonstrated little mast cell recurrence within 3 
weeks after their selective ablation using a different genetic system (Dudeck et al., 
2011). Both results corroborate the long-standing concept that, under steady-state 
conditions, mature connective tissue mast cells are rarely replaced by progenitors 
from the bone marrow (Kitamura et al., 1977). This is reminiscent of microglia in the 
central nervous system, Langerhans cells in the epidermis, Kupffer cells in the liver 
and macrophages in the serosal cavities (Gomez Perdiguero and Geissmann, 2013). 
These cells all originate from the yolk sac and their precursors migrate out into the 
periphery predominantly during embryonic development (Gomez Perdiguero and 
Geissmann, 2013). Similarly, mast cell colonies can be generated from yolk sac cells 
(Sonoda et al., 1983) and mast cell precursors peak in fetal blood around day 15 of 
gestation and subsequently seed the fetal skin (Hayashi et al., 1985; Rodewald et al., 
1996). However, it is presently unknown to what extent mast cells present in the adult 
are derived from this embryonic wave. Administration of 4-hydroxytamoxifen to 
pregnant R26-StopFYFP females crossed to KitCreERT2/+ males might allow mast cells 
and their c-Kit+ precursors to be pulse-labelled during embryogenesis and, hence, 
might give important insights into the developmental origin of mature mast cells.  
In summary, the novel KitCreERT2 mouse strain will be very useful to define the 
role of specific genes during physiological and pathological mast cell functions. The 
inducible nature of the Cre recombinase will furthermore facilitate studies of mast cell 
development, homeostasis and turnover.  
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